+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro release kinetics of timolol and timolol maleate from polyethylcyanoacrylate nanoparticles ii. nanoparticles manufactured with timolol maleate using different surfactants and organic solvents

In vitro release kinetics of timolol and timolol maleate from polyethylcyanoacrylate nanoparticles ii. nanoparticles manufactured with timolol maleate using different surfactants and organic solvents

Acta Pharmaceutica Fennica 101(2): 57-63

In this study the manufacturing of polyethylcyanoacrylate nanoparticles with timolol maleate by anionic polymerization was investigated. Different non-ionic surfactants and organic solvents were used for the solubilization of timolol maleate in order to polymerize these solubilized solutions with ethylcyanoacrylate. The effect of both, the drug and water concentration of the micelles on the in vitro drug release rate of the nanoparticles was studied. It was shown that the solubilization and polymerization were most successful using polyoxyethylated non-ionic surfactants and n-alkanes as solvents for solubilization. About 90 per cent of the initial timolol maleate concentration could be solubilized into the nanoparticles. The incorporation was neither affected by the drug concentration nor by the water content of the micelles. With this system a drug release rate of zero-order could not been achieved: the release of timolol maleate was rather controlled by its diffusion through the matrix following the cube root equation.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 007440220

Download citation: RISBibTeXText

Related references

In vitro release kinetics of timolol and timolol maleate from polyethylcyanoacrylate nanoparticles i. nanoparticles manufactured with timolol using nonionic surfactants in aqueous medium. Acta Pharmaceutica Fennica 101(1): 25-30, 1992

The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP. International Ophthalmology 38(4): 1425-1431, 2018

Timolol maleate 0.5% versus timolol maleate in gel forming solution 0.5% (Timolol GFS) in open angle glaucoma in India. Preliminary safety and efficacy study. Indian Journal of Ophthalmology 50(1): 21-23, 2002

Plasma levels and systemic safety of 0.1% unpreserved timolol maleate gel, 0.5% timolol aqueous solution and 0.5% timolol maleate gel. Journal Francais d'Ophtalmologie 35(1): 9, 2012

Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study. Clinical Therapeutics 31(10): 2063-2071, 2009

Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Documenta Ophthalmologica. Advances in Ophthalmology 103(1): 73-79, 2001

Efficacy and Safety of Latanoprost/Timolol Maleate Fixed Combination Verses Timolol Maleate and Brimonidine Given Twice Daily. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 3430, 2002

Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmologica Scandinavica 81(3): 242-246, 2003

Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye 18(12): 1264-1269, 2004

The effect of timolol maleate 05% gel and timolol maleate 05% solution twice daily versus placebo on pulmonary function in older primary open-angle glaucoma or ocular hypertensive patients. IOVS 41(4): S515, 2000

A comparison of the ocular hypotensive effect of dorzolamide hydrochloride/timolol maleate to that of the concomitant therapy with brimonidine tartate and timolol maleate in patients with ocular hypertension or primary open-angle glaucoma. IOVS 42(4): S822, 2001

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops. Clinical Ophthalmology 9: 619-623, 2015

Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clinical Therapeutics 21(1): 138-147, 1999

Comparison of the efficacy on intraocular pressure and retinal blood flow of a beta-blocker (timolol maleate) against the fixed association of a topical carbonic anhydrase (dorzolamide) and a beta-blocker (timolol maleate). Acta Ophthalmologica Scandinavica. Supplement 2000(232): 47-49, 2000

Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. Acta Ophthalmologica Scandinavica 80(3): 277-281, 2002